Jiangsu Hualan New Pharmaceutical Material Co., Ltd.

Jiangsu Hualan New Pharmaceutical Material Co., Ltd. has shown strong stock performance, significantly outperforming the China Shanghai Composite over various time frames. Despite impressive annual returns, the company faces challenges such as low Return on Capital Employed and declining net sales, with a market capitalization of CNY 12,456 million.

Jiangsu Hualan New Pharmaceutical Material Co., Ltd. experienced notable stock activity, rising significantly today and achieving a substantial one-year gain. Despite this strong performance, the company faces challenges related to management efficiency and profitability, highlighted by a low Return on Capital Employed and declining net sales over recent years.

Jiangsu Hualan New Pharmaceutical Material Co., Ltd. saw a notable stock decline today, contrasting with the broader market's performance. Despite a remarkable annual growth of over 263%, the company faces challenges, including low management efficiency and negative sales results for three consecutive quarters, alongside a high P/E ratio.

Jiangsu Hualan New Pharmaceutical Material Co., Ltd. has seen significant stock performance, with a notable increase on March 20, 2026, contrasting with a decline in the broader market. Despite impressive annual gains, the company faces challenges such as low ROCE and declining net sales over five years.

Jiangsu Hualan New Pharmaceutical Material Co., Ltd. has seen a notable rise in its stock performance, significantly outperforming the China Shanghai Composite index over various timeframes. Despite impressive annual growth, the company faces challenges such as low management efficiency and declining net sales in recent years.

Jiangsu Hualan New Pharmaceutical Material Co., Ltd. saw its stock price decline today, contrasting with a slight increase in the China Shanghai Composite. Despite a recent weekly gain, the company has faced challenges, including negative results over the last three quarters and a low Return on Capital Employed.

Jiangsu Hualan New Pharmaceutical Material Co., Ltd. has seen notable stock activity, significantly outperforming the China Shanghai Composite. While the company has achieved impressive short-term gains and a remarkable one-year performance, it faces challenges in management efficiency and declining net sales and operating profit over the past five years.

Jiangsu Hualan New Pharmaceutical Material Co., Ltd. saw a notable rise on March 5, 2026, contrasting with a decline in the China Shanghai Composite. The company has shown impressive annual growth but faces challenges such as low Return on Capital Employed and declining net sales over five years.

Jiangsu Hualan New Pharmaceutical Material Co., Ltd. saw its stock price decline significantly today, contrasting with the broader market. Despite a remarkable annual growth of nearly 298%, the company faces financial challenges, including low profitability metrics and declining sales and profits over recent years.

Jiangsu Hualan New Pharmaceutical Material Co., Ltd. faced a significant stock price decline on March 3, 2026, reaching an intraday low. Despite a strong annual performance, recent trends show challenges, including negative results for three consecutive quarters and concerns over management efficiency, reflected in its ROCE and high P/E ratio.

Jiangsu Hualan New Pharmaceutical Material Co., Ltd. faced a significant stock decline today, marking a challenging trading period. The company has struggled recently, with a notable decrease over the past week and consecutive quarterly losses. Financial metrics reveal low profitability and a high price-to-earnings ratio, suggesting valuation concerns.